SRRK — Scholar Rock Holding Corp

—
Nasdaq · Health Care · Biotechnology · CIK 1727196 ·
Last close
$45.08
Market Cap
$5.50B
52W High
$61.76
52W Low
$36.78
ADV30
1,726,088
Next earnings
2026-11-10
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 570,000 562,000 -106,061,000 -107,239,000 445,972,000 366,269,000 277,296,000
Jun 2026 0 — -108,901,000 -109,896,000 523,543,000 437,091,000 269,759,000
Mar 2026 0 — -102,016,000 -105,510,000 535,254,000 430,543,000 259,241,000
Dec 2025 0 — -91,896,000 -90,965,000 404,272,000 323,527,000 158,784,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-309,711,000
Investing CF
$36,077,000
Financing CF
$353,318,000
CapEx
$-202,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.36
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,623,299,000
Inventory
$773,000
Receivables
$2,368,000
ST Investments
$47,330,000
EBIT TTM
$-399,622,000
Pretax Income TTM
$-413,610,000
Interest Exp TTM
$13,988,000
Analysts
16

Yahoo Snapshot (yfinance, live)

Total Revenue
$570,000
EBITDA
$-407,559,008
Free Cash Flow
$-168,629,744
Enterprise Value
$5,060,597,248
Total Cash
$413,599,008
Total Debt
$202,992,992
Shares Out
122,004,478
Trailing EPS
$-3.23
Book Value
$1.38
ROE
-200.0%
ROA
-59.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -384,645,000 -377,939,000 404,272,000 158,784,000 245,488,000 -300,035,000
Dec 2024 0 -252,054,000 -246,294,000 474,922,000 106,288,000 368,634,000 -200,949,000
Dec 2023 0 -171,295,000 -165,789,000 311,035,000 85,817,000 225,218,000 -145,226,000
Dec 2022 33,193,000 -134,370,000 -134,502,000 358,168,000 97,933,000 260,235,000 -132,694,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-408,591,000
OpCashFlow TTM
—
Assets (Latest)
$523,543,000
Forward EPS
$-2.45

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $55.00 · spot: $48.00 · call volume: 179 · put volume: 1,638
Expected Move to 2027-01-15: ±$8.06 (16.79%) — implied range $39.94 – $56.06 · ATM straddle on $50.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
KOD Kodiak Sciences Inc. $6.33B $96.80 —
ADPT Adaptive Biotechnologies Corp $4.61B $28.49 —
IBRX ImmunityBio, Inc. $6.66B $6.26 —
IMVT Immunovant, Inc. $6.87B $33.21 —
CGON CG Oncology, Inc. $7.00B $78.94 —

News headlines (Yahoo Finance, 1h cache)

Scholar Rock to Present at Upcoming Investor Conferences
2026-11-17 13:00 · Yahoo
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-13 21:15 · Yahoo
Scholar Rock (SRRK) Q3 2026 Earnings Call Transcript
2026-11-10 19:31 · Yahoo
What Scholar Rock (SRRK) Said on Its Q3 Earnings Call
2026-11-10 18:15 · Yahoo
Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Beats Revenue Estimates
2026-11-10 12:05 · Yahoo
Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-10 12:00 · Yahoo
Scholar Rock (SRRK) Stock Could Trade At A Premium On Balance Sheet Hopes
2026-10-30 09:13 · Yahoo
EMA Resubmission for Apitegromab Might Change The Case For Investing In Scholar Rock Holding (SRRK)
2026-10-16 01:20 · Yahoo
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
2026-10-08 12:00 · Yahoo
3 drug targets pharma is betting on next
2026-10-02 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.